Celularity (CELU) Non-Current Assets (2018 - 2025)
Celularity's (CELU) quarterly Non-Current Assets came in at -$12.0 million in Q4 2025, down 110.69% year-over-year from $112.1 million in Q4 2024, and down 111.56% quarter-over-quarter from $103.6 million in Q3 2025.
Analysis
Celularity (CELU) Non-Current Assets (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Non-Current Assets for 8 consecutive years, with -$12.0 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Non-Current Assets fell 110.69% year-over-year to -$12.0 million in Q4 2025; TTM through Dec 2025 was $301.5 million, a 35.19% decrease from a year earlier, with the FY2025 full-year figure at -$12.0 million, down 110.69% from the prior year.
- Non-Current Assets was -$12.0 million for Q4 2025 at Celularity, down from $103.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $374.0 million in Q3 2022 and troughed at -$12.0 million in Q4 2025.
- A 5-year average of $209.2 million and a median of $134.5 million in 2021 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets soared 175.7% in 2022 and tumbled 110.69% in 2025, its largest moves.
- Over 5 years, Non-Current Assets stood at $355.0 million in 2021, then rose by 3.53% to $367.6 million in 2022, then slumped by 66.24% to $124.1 million in 2023, then retreated by 9.65% to $112.1 million in 2024, then plunged by 110.69% to -$12.0 million in 2025.
- The last three Non-Current Assets figures came in at -$12.0 million (Q4 2025), $103.6 million (Q3 2025), and $103.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 441.00 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 279.00 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 451.27 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 523.50 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 150.83 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 207.76 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 35.91 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 964.69 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 238.14 Mn |
| 10 | Celularity | 36.35 Mn | 30.17 Mn | -3.27 Mn | -11.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -11.98 Mn |
| Sep 30, 2025 | 103.64 Mn |
| Jun 30, 2025 | 103.02 Mn |
| Mar 31, 2025 | 106.80 Mn |
| Dec 31, 2024 | 112.12 Mn |
| Sep 30, 2024 | 114.34 Mn |
| Jun 30, 2024 | 117.76 Mn |
| Mar 31, 2024 | 120.96 Mn |
| Dec 31, 2023 | 124.10 Mn |
| Sep 30, 2023 | 140.69 Mn |
| Jun 30, 2023 | 228.38 Mn |
| Mar 31, 2023 | 337.41 Mn |
| Dec 31, 2022 | 367.56 Mn |
| Sep 30, 2022 | 374.02 Mn |
| Jun 30, 2022 | 353.88 Mn |
| Mar 31, 2022 | 358.46 Mn |
| Dec 31, 2021 | 355.03 Mn |
| Sep 30, 2021 | 357.01 Mn |
| Jun 30, 2021 | 128.36 Mn |
| Mar 31, 2021 | 291.83 Mn |